Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-15 4:29 pm Sale | 13D | NewAmsterdam Pharma Co N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 11,820,563 12.800% | -10,898 (-0.09%) | View |
| 2024-11-14 07:00 am Sale | 13G | Dyne Therapeutics Inc. DYN | Forbion Capital Fund IV Cooperatief U.A. | 5,795,364 5.800% | -335,715 (-5.48%) | View |
| 2023-07-07 5:06 pm Purchase | 13D | NewAmsterdam Pharma Co N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 11,831,461 14.500% | 3,589,061 (+43.54%) | View |
| 2023-07-07 5:00 pm Purchase | 13D | NewAmsterdam Pharma Co N.V. NAMS | Forbion Capital Fund IV Cooperatief U.A. | 8,242,400 10.100% | 8,242,400 (New Position) | View |
| 2022-02-11 09:20 am Purchase | 13G | Achilles Therapeutics plc ACHL | Forbion Capital Fund IV Cooperatief U.A. | 2,390,050 5.890% | 2,390,050 (New Position) | View |
| 2021-02-16 06:38 am Purchase | 13G | Dyne Therapeutics Inc. DYN | Forbion Capital Fund IV Cooperatief U.A. | 6,131,079 13.490% | 6,131,079 (New Position) | View |